Please assess the completion status of the following clinical trial:

Trial Title: Dasatinib Versus Nilotinib for Treatment Naïve Chronic Myeloid Leukemia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Male or female patients 18 years or over.~2. Patients must have all of the following:~   * be enrolled within 3 months of initial diagnosis of CML-CP (Chronic Phase) (date of initial diagnosis is the date of first cytogenetic analysis)~  * cytogenetic confirmation of the Philadelphia chromosome or variants of (9;22) translocations~  * patients may have secondary chromosomal abnormalities in addition to the Philadelphia chromosome.~  * \< 15% blasts in peripheral blood and bone marrow;~  * \< 30% blasts plus promyelocytes in peripheral blood and bone marrow;~  * \< 20% basophils in peripheral blood,~  * 100 x 109/L platelets or greater~  * no evidence of extramedullary leukaemic involvement, with the exception of the hepatosplenomegaly.~3. Written voluntary informed consent.~Exclusion Criteria:~1 - Patients with Ph-negative, BCR-ABL-positive, disease are NOT eligible for the study.~2. Any prior treatment for CML with: any tyrosine kinase inhibitor (eg imatinib, dasatinib); busulphan; interferon-alpha; homoharringtonine; cytosine arabinoside; any other investigational agents (hydroxycarbamide and anagrelide are the only drugs permitted). Patients will be ineligible for the study if they have received any prior therapy with interferon-alpha or imatinib. No exceptions.~3. Patients who received prior chemotherapy, including regimens used in peripheral blood progenitor cells (PBPCs) mobilisation for haematopoietic progenitor-cell transplantation. (It is allowable to collect unmobilised PBPCs at diagnosis.) 4. Patient who have had any form of prior haemopoietic stem cell transplant, either autograft or allograft.~5. Patients with an ECOG (Eastern Cooperative Oncology Group) Performance Status Score of 2 or less.~6. Patients with serum bilirubin, AST (aspartate aminotransferase), ALT (alanine aminotransferase), or creatinine concentrations \> 2.0 x the institutional upper limit of the normal range (IULN).~7. Patients with International normalized ratio (INR) or partial thromboplastin time (PTT) \> 1.5 x IULN, with the exception of patients on treatment with oral anticoagulants.~8. Patients with uncontrolled medical disease such as diabetes mellitus, thyroid dysfunction, neuropsychiatric disorders, infection, angina, or Grade 3/4 cardiac problems as defined by the New York Heart Association Criteria.~9. Patients with known positivity for human immunodeficiency virus (HIV); baseline testing for HIV is not required.~10. Patients who have undergone major surgery within 4 weeks of Study Day 1, or who have not recovered from prior major surgery.~11. Patients who are:~* pregnant,~* breast feeding,~* of childbearing potential without a negative pregnancy test prior to Study Day 1, and~* male or female of childbearing potential unwilling to use barrier contraceptive precautions throughout the trial (postmenopausal women must be amenorrheic for at least 12 months to be considered of non-childbearing potential).~  12. Patients with a history of another malignancy either currently or within the past five years, with the exception of basal cell skin carcinoma or cervical carcinoma in situ.~  13. Patients with a history of non-compliance to medical regimens or who are considered potentially unreliable

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Dasatinib (Type: ACTIVE_COMPARATOR): Dasatinib 100mg, once daily (QD), will be given to 25 patients, orally
- Nilotinib (Type: EXPERIMENTAL): Nilotinib 300mg, twice daily (BID), will be given to 25 patients, orally

Based on this trial design, predict the completion outcome and termination type (if applicable).